Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The small cell lung cancer (SCLC) treatment landscape is rapidly evolving, with antibody-drug conjugates (ADCs) and T-cell engagers emerging as potential new standards of care. Phase 3 trial data from DeLLphi-305 showed tarlatamab plus durvalumab nearly doubled overall survival versus durvalumab alone in first-line maintenance. Oncology expert Dr. Misty Shields breaks down what these advances mean for treatment sequencing, molecular subtyping, and patients with transformed SCLC.
The extensive-stage small cell lung cancer (ES-SCLC) treatment landscape is undergoing a dramatic shift, with 2026 data from major oncology congresses pointing to antibody-drug conjugates (ADCs) and T-cell engagers as the next wave of standards of care. At the 2026 ESMO Congress, the phase 3 DeLLphi-305 trial showed that tarlatamab plus durvalumab delivered a median overall survival (OS) of 21.1 months in first-line maintenance — nearly double the 12.7 months seen with durvalumab alone. Two B7-H3–directed ADCs, tambotatug pelitecan and risvutatug rezetecan, also outperformed topotecan in relapsed SCLC, with meaningful OS improvements in both trials.
SCLC expert Dr. Misty Shields weighed in on the pressing clinical questions these results raise — from how to sequence ADCs and T-cell engagers to the role of CAR T-cell therapy and molecular subtyping. She noted that biomarker discovery will be critical to guide treatment decisions, especially as multiple agents compete for similar lines of therapy.
By the Numbers:
Why it matters: These results signal a potential shift away from decades of chemotherapy-dominated SCLC treatment, offering patients meaningfully longer survival — but also raising urgent questions about sequencing, access, and biomarker-guided care that clinicians will need to navigate in the near future.
